news
Experimental antiviral AR-12 could be a promising COVID-19 treatment
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
List view / Grid view
US Food and Drug Administration (FDA)
article
Cocaine and the brain: identifying targets for addiction therapies
There are currently no licenced pharmaceuticals to treat cocaine addiction. To overcome this issue, US researchers at the University of Alabama at Birmingham have been exploring how cocaine alters transcription in the nucleus accumbens, a region of the brain implicated in compulsive drug use. Here, Hannah Balfour discusses with Dr…
article
COVID-19 therapies in the pipeline
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
news
AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
news
Natural killer cells aid in breast cancer metastasis, reports study
Researchers found breast cancer cells reprogrammed natural killer T cells, altering gene expression and receptor expression so they help cancerous metastases spread.
news
Novel vitamin K analogue eliminates seizure activity in epileptic mouse models
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
news
Novel class of non-addictive analgesics demonstrate safety in animals
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
news
Novel compound could treat type 2 diabetes without common side effects
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
article
Targeting SARM1 to protect vision across retinal degenerative diseases
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
article
Using genetics to identify drug targets for fibrotic lung diseases
Researchers recently conducted a genome-wide association study (GWAS) to identify factors that increase susceptibility to the incurable lung condition idiopathic pulmonary fibrosis (IPF). Here, Dr Richard Allen shares some of the study’s key findings.
article
Delivering a therapy to kerb COVID-19
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
article
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
article
Utilising an interleukin-12 plasmid: a novel COVID-19 vaccine
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
news
Blueprint for adapting US labs for COVID-19 diagnostic testing
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
